CVS Health announced on Wednesday that it will split itself into two publicly traded companies, unwinding the vertically integrated health care empire it spent years building through acquisitions. The separation, expected to be completed in the first half of 2028, will spin off the company's roughly 9,000 retail pharmacies into a standalone business, while its Aetna health insurance arm and Caremark pharmacy benefits manager stay together under the CVS Health name.
 |
| File photo: A CVS/pharmacy store. CVS Health announced on November 4, 2026, that it will spin off its roughly 9,000 retail pharmacies into a separate publicly traded company. (Matthews) |
The announcement, made alongside third-quarter earnings that beat Wall Street expectations, is one of the largest corporate breakups in American history. Yet investors greeted it with a sell-off: CVS shares closed down 12.5 percent at $79.96 on Wednesday, wiping nearly $15 billion off the company's market value, according to Reuters.
How the Two Companies Will Look
Under the plan, which follows what the company called a comprehensive strategic review by its board, the two businesses will be built along clean lines.
One company will keep the CVS Health name, at least for now, and will be led by current chairman and chief executive David Joyner. It will hold Aetna, one of the nation's largest health insurers; CVS Caremark, one of the country's three largest pharmacy benefit managers; the specialty pharmacy business; Oak Street Health, the primary care provider; and Signify Health, the home-based care business.
The second company, to be called CVS Pharmacy, will be led by Prem Shah, currently a group president at CVS Health. It will include the roughly 9,000 retail drugstores, the mail-order pharmacy, the MinuteClinic walk-in clinics, and Health100, a technology business the company says will deliver artificial intelligence-native products and services.
Current shareholders will own shares in both companies once the separation is complete, and CVS intends the transaction to be tax-free for U.S. federal income tax purposes. The split still needs final approval from the company's board and an effective Form 10 registration statement filed with the Securities and Exchange Commission. CVS has not yet said which company will keep the CVS stock ticker, or what the share ratio will be.
 |
| File photo: The Aetna insurance building in Hartford, Connecticut. Aetna will stay with CVS Caremark in the company that keeps the CVS Health name after the split. (Wikimedia Commons) |
A Reversal Years in the Making
The breakup reverses a strategy that defined an era of health industry gigantism. CVS bought the Caremark pharmacy benefit manager in 2006, then completed its acquisition of insurer Aetna in 2018, knitting together a chain of drugstores, an insurer, a middleman that negotiates drug prices, and, later, clinics and home health services — all under one roof.
The logic at the time was that owning every link in the chain would let CVS steer patients from the doctor's office to the pharmacy counter to the insurance claim, cutting costs and keeping more of the spending in-house. For years, rivals followed the same playbook.
That era is ending. Reuters described the planned breakup as the latest in a series of major corporate splits this decade, as companies look to simplify sprawling operations. For CVS, the split would return it to being a standalone pharmacy chain for the first time since 2006.
Chief Executive David Joyner, who took over in October 2024, framed the move as a choice made from strength rather than desperation. "From a position of strength, and a focus on the long term, we plan to create two focused companies to improve consumer engagement, affordability, and care coordination," he said in the company's announcement.
The numbers give him something to point to. CVS reported third-quarter sales of $108.40 billion, up from $102.87 billion in the same period a year earlier, and forecast 2027 adjusted earnings of at least $8.65 per share, ahead of analysts' estimates of $8.53. The company said it has now beaten and raised its guidance for eight consecutive quarters, and its shares have risen roughly 70 percent since Joyner took the helm, lifting its market value to about $117 billion.
Behind those headline figures sits a turnaround effort that has included $2 billion in cost cuts, store closures, leadership shakeups, and a push to rein in costs in its Medicare Advantage business. Aetna's margins, which had been a drag on results, continued to recover in the third quarter as medical costs in its government business came down.
Wall Street's Verdict: Not Convinced Yet
If Joyner presented the split as a position of strength, the market answered with doubt. Shares fell about 10 percent in early trading on Wednesday and closed down 12.5 percent, even though the quarter beat estimates and the company raised its outlook.
Analysts and investors raised several questions. The separation will take more than a year to complete, and until then investors face separation costs and execution risk before they can value each business on its own. CVS also carries about $60.7 billion in debt, and how that debt — and the company's dividend — is divided between the two new firms will matter greatly to shareholders.
There is also a deeper question about whether the split actually solves the problem it is meant to address. Critics of vertically integrated health care companies have long argued that owning both an insurer and the pharmacy benefit manager that decides which drugs get covered creates a conflict of interest. Under CVS's plan, Aetna and Caremark stay together in the same company, alongside the specialty pharmacy business. As MedCity News put it, the company is bidding goodbye to vertical integration but not to the conflict of interest at the heart of the criticism.
Joyner told investors that the stores and Caremark already deal with each other at arm's length, and that commercial agreements between the two new companies will preserve their joint products.
Washington Was Watching
The split also comes as the political pressure on companies like CVS has intensified from both parties. Joyner himself acknowledged that regulation was one of the factors the company considered.
In Washington, a bipartisan bill called the Break Up Big Medicine Act, sponsored by Senators Elizabeth Warren, a Massachusetts Democrat, and Josh Hawley, a Missouri Republican, would require companies like CVS to separate their insurers, pharmacy benefit managers, and provider businesses into independent entities. A related proposal, the Patients Before Monopolies Act, would bar any company that owns an insurer or a benefit manager from owning a pharmacy, and its text explicitly counts specialty pharmacies — which, under the CVS plan, would remain with the insurer. Tennessee and Arkansas have already passed laws banning the co-ownership of pharmacy benefit managers and pharmacies, which CVS is challenging in court.
Against that backdrop, splitting off the drugstores voluntarily lets CVS get ahead of a forced breakup — on its own terms and its own timetable — while keeping the insurer and the benefit manager, the parts of the business that generate the steadiest profits, together
 |
| File photo: A pharmacist counts medication at a pharmacy counter. CVS says the split will not affect what patients pay for prescriptions. (Wolters Kluwer) |
What This Means
For the millions of Americans who fill prescriptions at a CVS, the company says nothing will change in the near term. CVS has announced no store closures as part of the split, and it says the separation will not affect what patients pay for prescriptions.
For shareholders, the next year will be a test of whether two focused companies are worth more than one sprawling one. The drugstore business, freed from the insurer, will have to prove it can grow on its own in a retail pharmacy market that has been shrinking. The health care solutions company, meanwhile, will have to show that Aetna, Caremark, Oak Street, and Signify can grow together without the foot traffic the drugstores provided.
For the wider health care industry, the split is a signal. The vertically integrated model that defined the last decade — one company owning the insurer, the drug middleman, the pharmacy, and the clinic — is now being unwound by its own architects.
And for Washington, the announcement may not settle the debate. If Aetna and Caremark remain under one roof, the lawmakers who want the industry broken up are likely to keep pushing.
What Happens Next
The separation is expected to be completed in the first half of 2028, giving CVS more than a year to execute the transition. In the meantime, the company must secure final board approval, file its Form 10 registration with the Securities and Exchange Commission, and confirm the tax-free treatment of the deal.
Investors will be watching the details that remain undecided: which company keeps the CVS ticker, how the shares will be divided, how the debt is split, and what happens to the dividend. The first full test will come in the coming quarters, as the company reports results while preparing to divide itself — and as Washington decides whether a voluntary split is enough.
Post a Comment